ArticleArthritis research & therapy2022
The difference of lipid profiles between psoriasis with arthritis and psoriasis without arthritis and sex-specific downregulation of methotrexate on the apolipoprotein B/apolipoprotein A-1 ratio.
Article in Arthritis research & therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 20 citations in OpenAlex.
- Article
- Altered Lipid Metabolism in Psoriatic Arthritis: A Comprehensive Review.Metabolites · 2026Review
- Lipoprotein (a) levels are elevated in psoriasis: An updated systematic review and meta-analysis.World journal of clinical cases · 2025Article
- Systematic genetic investigation on relative macronutrient intake, circulating metabolic biomarkers and the risk of autoimmune diseases.NPJ science of food · 2025Article
- Methotrexate associates with ischemic cardiovascular risk reduction in males but not females: a transatlantic cardiovascular consortium for people with rheumatoid arthritis observational study.Rheumatology international · 2025Observational
- Inflammatory Pathways to Carcinogenesis: Deciphering the Rheumatoid Arthritis-Lung Cancer Connection.Cancers · 2025Review
- Apolipoproteins in Psoriasis: The Effect of Acitretin Treatment and UVB Phototherapy.Metabolites · 2025Article
- Low apolipoprotein A1 and high apolipoprotein B levels indicate specific lipid changes in treatment naïve early psoriatic arthritis.RMD open · 2025Article
- Unveiling the skin microbial guardians and assailants in psoriasis subtypes: a Mendelian randomization study.Archives of dermatological research · 2024Article
- Metabolomic Alterations in Methotrexate Treatment of Moderate-to-Severe Psoriasis.Medical science monitor : international medical journal of experimental and clinical research · 2024Article
- Knowledge, attitude, and practice of psoriatic arthritis among patients with psoriasis.Frontiers in medicine · 2024Article
- Unraveling the Pleiotropic Role of High-Density Lipoproteins (HDLs) in Autoimmune Rheumatic Diseases.International journal of rheumatology · 2024Review
- Association between psoriasis and serum apolipoprotein A1 and B: A systematic review and meta-analysis.Heliyon · 2023Review
- The Role of Sphingolipids in the Pathogenesis of Psoriasis.Metabolites · 2022Review
- Case-Control Study to Investigate the Association Between Serum Apolipoprotein B/A1 Ratio and Atrial Fibrillation by Sex in 920 Patients from China.Medical science monitor : international medical journal of experimental and clinical research · 2022Article
- Methotrexate and cardiovascular prevention: an appraisal of the current evidence.Therapeutic advances in cardiovascular diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMethotrexate (MTX) has a protective effect against cardiovascular diseases (CVD), but the mechanism is unclear.
objectiveTo investigate the effect of MTX on lipid profiles and the difference between psoriasis without arthritis (PsO) and psoriatic arthritis (PsA).
methodsIn this prospective study, we recruited 288 psoriatic patients (136 PsA and 152 PsO) who completed 12 weeks of MTX treatment. Total cholesterol (TC), triglycerides (TG), lipoprotein A [LP(a)], high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein (LDL), apolipoprotein A1 (ApoA1), and ApoB were measured.
resultsCompared with sex- and age-matched healthy controls, psoriatic patients had significantly (p < 0.0001) higher levels of proatherogenic lipids and lower levels of anti-atherogenic lipids. PsA patients had a higher ApoB/ApoA1 ratio than PsO patients (p < 0.05). Stepwise regression analysis found a positive correlation between the inflammatory marker hCRP and the Psoriasis Area Severity Index (PASI), ApoB/ApoA1 ratio, BMI, and smoking. ApoB was positively associated with concomitant arthritis, diabetes, and hypertension. MTX decreased the levels of pro-atherogenic and anti-atherogenic lipids. However, a significant reduction of the ApoB/ApoA1 ratio by MTX was only observed in male patients.
conclusionPsA patients had a significantly higher percentage of concomitant disease than PsO. The decrease of MTX on CVD might be related with sex.
trial registrationChiCTR2000036192.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.